@FiercePharma: Roche is putting $900M into biologics manufacturing, but turning to Samsung for some of its drugs. News | Follow @FiercePharma
@CarlyHFierce: Here's FiercePharmaManufacturing's take on McKesson's Celesio buyout. More | Follow @CarlyHFierce
> The U.K.'s cost-effectiveness watchdogs refused to back Celgene's ($CELG) blood cancer drug Revlimid for a new use in a rare bone marrow disorder. Report
> Omnicare agreed to pay $120 million to settle a U.S. kickback lawsuit, which alleges that the pharmacy services provider gave nursing homes heavily discounted drugs in exchange for patient referrals. Report
> Cubist Pharmaceuticals ($CBST) posted third-quarter earnings of 41 cents per share, far short of the expected 55 cents, because of higher expenses; sales rose by 12% to $266 million. Report
> The FDA said it's completing its phase-out of all drug inhalers containing CFCs by Dec. 31 to comply with an international treaty. Release
> Sanofi ($SNY) moved all its human resources operations in more than 100 countries into the cloud to allow for new global processes and data analytics. Report
> China's Sinopharm said its 9-month net profit rose 17.5%. Report
> GlaxoSmithKline ($GSK) is eyeing a new advertising agency for its global digital advertising. Report
> Novo Nordisk ($NVO) said it's worried about illegal online sales of its growth hormone, some of which probably isn't genuine. Report
> The U.K.'s National Health Service hired Simon Stevens to take over as CEO next year; Stevens currently heads up the global health division of U.S.-based insurer UnitedHealth. Report
> As it prepares to be acquired by Perrigo ($PRGO), Elan ($ELN) posted earnings before interest and taxes of $12.1 million and said it has $1.9 billion in cash on hand. Report
@FierceMedDev: UPDATED: Boston Scientific to slash up to 1,500 more jobs even as Q3 numbers improve. Story | Follow @FierceMedDev
@MarkHFierce: Check out this week's FierceDiagnostics newsletter | Follow @MarkHFierce
@MichaelGFierce: Layered nanoparticles deliver RNA, chemo for one-two punch. Item from FierceDrugDelivery | Follow @MichaelGFierce
> Med tech VC Versant raising $250M new fund amid sluggish market. Story
> Vitamin B2 may help build a safer 3-D medical implant. Item
> Zimmer lowers outlook as profits slide despite ortho growth. Report
> DeCODE spinout raises $15M to bring gene sequencing into daily Dx. Article
Biotech News
@FierceBiotech: ICYMI yesterday: The top 10 biotech IPOs of 2013. Special report | Follow @FierceBiotech
@JohnCFierce: Rigel sinks after adding another trial failure to its losing streak. News | Follow @JohnCFierce
@DamianFierce: Repros tanks as FDA scrutiny of testosterone drug pushes back NDA date. ICYMI yesterday | Follow @DamianFierce
@EmilyMFierce: ICYMI: Takeda, Hopkins developing new pancreatic cancer drugs. More from FierceBiotech Research | Follow @EmilyMFierce
> Armed-antibody successes inspire a burst of new building projects, industry deals. More
> Troubled Merck shrugs off fresh doubts about late-stage heart drug. Article
> Bristol-Myers exec sentenced to a year in prison on insider trading scheme. Report
> AstraZeneca plans to shutter lab, ax staffers. Item
Pharma Manufacturing News
@EricPFierce: Samsung, which has worked on a biosimilar of Rituxan, has a new deal to make biologics for Roche. Article | Follow @EricPFierce
> Stolen Novo growth hormone sold on Internet. Item
> McKesson makes $8.3B move on Europe. Story
> Actis invests $48M in API maker Symbiotec. News
> Hospira unveils new quality lab at troubled plant. More
Vaccines News
> Finnish team talks up prospects of Type 1 diabetes vaccine. Report
> Study finds herd immunity protects babies against whooping cough. More
> Meta-analysis links flu vaccine to lower risk of heart attack and stroke. Article
> Timing of first measles vaccine dose linked to effectiveness. Item
> Taliban anti-vaccine push raises risk of polio outbreak. Story
And Finally... Prostate cancer radiation therapy is more commonly prescribed by urologists who own their own equipment to provide the treatment. Report